Report cover image

Zika virus infection - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 50 Pages
SKU # DEL18680221

Description

Zika virus infection - Pipeline Insight, 2024



DelveInsight’s, “Zika Virus Infection - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Zika Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Zika Virus Infection Understanding

Zika Virus Infection: Overview

Zika fever is a mosquito-borne viral disease caused by Zika virus (ZIKV), consisting of mild fever, rash (mostly maculo-papular), headaches, arthralgia, myalgia, asthenia, and non-purulent conjunctivitis, occurring about two to seven days after the mosquito vector bite. Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). The symptoms typically last for 2-7 days. The diagnosis of the virus is done through a blood test. Zika virus infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, known as congenital Zika syndrome. Infection with Zika virus is also associated with other complications of pregnancy including preterm birth and miscarriage. Treatment consists of relieving pain, fever, and any other symptom that inconveniences the patient. To prevent dehydration, it is recommended to control the fever, rest, and drink plenty of water.

""Zika Virus Infection - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Zika Virus Infection pipeline landscape is provided which includes the disease overview and Zika Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Zika Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Zika Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Zika Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Zika Virus Infection.
Zika Virus Infection Emerging Drugs Chapters

This segment of the Zika Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Zika Virus Infection Emerging Drugs
  • mRNA-1893: Moderna Therapeutics
mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection. The drug is in Phase II clinical studies for the treatment of Zika Virus Infection. In August 2019, Moderna announced that the US FDA has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) for the prevention of Zika virus infection in healthy adults.
  • GLS-5700: GeneOne Life Science
GLS-5700 is a DNA vaccine encoding the pre-membrane and envelop (prM-E) proteins of Zika virus (ZIKV). It is being developed by Geneone life science for Zika Virus Infection and is currently in Phase I stage of development.

Further product details are provided in the report……..

Zika Virus Infection: Therapeutic Assessment

This segment of the report provides insights about the different Zika Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Zika Virus Infection
There are approx. 12+ key companies which are developing the therapies for Zika Virus Infection. The companies which have their Zika Virus Infection drug candidates in the most advanced stage, i.e. Phase II include, Moderna Therapeutics.
  • Phases
DelveInsight’s report covers around 12+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Zika Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Zika Virus Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Zika Virus Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Zika Virus Infection drugs.

Zika Virus Infection Report Insights
  • Zika Virus Infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Zika Virus Infection Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Zika Virus Infection drugs?
  • How many Zika Virus Infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Zika Virus Infection?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Zika Virus Infection therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Zika Virus Infection and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Moderna Therapeutics
  • GeneOne Life Science
  • WuXi Biologics
  • Inovio Pharmaceuticals
  • Takeda
  • Emergex Vaccines
  • Rigel Pharmaceuticals
  • Ala Wai Pharma Australia
  • Immunomodulation
  • Greffex
  • Biotron
Key Products
  • mRNA 1893
  • GLS-5700
  • Tyzivumab
  • INO-A002
  • TAK 426
  • EMX 001
  • Bemcentinib
  • Niclosamide
  • Annexin A5
  • Research programme: DNA vaccines
  • BIT 009

Table of Contents

50 Pages
Introduction
Executive Summary
Zika Virus Infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Zika Virus Infection – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
mRNA 1893: Moderna Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Tyzivumab: Tychan/WuXi Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
EMX 001: Emergex Vaccines
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Zika Virus Infection Key Companies
Zika Virus Infection Key Products
Zika Virus Infection- Unmet Needs
Zika Virus Infection- Market Drivers and Barriers
Zika Virus Infection- Future Perspectives and Conclusion
Zika Virus Infection Analyst Views
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us